SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

Slap is trending as the community rallies around the crypto, expressing bullish sentiment and encouraging others to "slap" the ask. The coin's community is actively promoting the project and celebrating its resilience in the market, using the hashtag $SLAP.

COTI is a fast and light confidentiality layer on Ethereum. Powered by the breakthrough cryptographic protocol Garbled Circuits and secured by Ethereum, COTI introduces the most advanced and compliant solution for data protection on the public blockchain. Paving the way for the next wave of Web3 innovation and adoption, COTI unlocks a whole new world of use cases, including confidential transactions, Artificial Intelligence, DeFi, decentralized identification, and more.

COTI

COTI is trending as the community discusses its potential in the privacy sector, drawing comparisons to other privacy coins like ZEC and XMR. There's excitement around upcoming developments, including mainnet launch and AI integrations, with some viewing it as an undervalued gem. Community members are actively speculating on potential price targets and expressing bullish sentiment.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin (FIL) is trending as traders discuss its potential as a value play and competitor to Amazon's AWS, with some drawing comparisons to ZEC's past performance; the community is closely watching key breakout levels and anticipating a continued upward trend amid the broader altcoin season, while others are noting the circulating supply.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is gaining traction, particularly within communities focused on Solana projects, as some traders highlight its resilience during market dips. Bullish sentiment appears to be building around the token, with community members actively discussing potential future gains and encouraging others to get involved. Talk is centered around community support from groups such as Broke Coin and its relation to projects deemed to 'slap'.

Townsquare Media, Inc. is a community-focused digital media, digital marketing solutions and radio company, which engages in owning and operating radio stations, digital and social properties and live events in small and mid-sized markets across the United States. It operates through the following business segments: Subscription Digital Marketing Solutions, Digital Advertising, Broadcast Advertising, Other, and Corporate. The company was founded by Alexander Berkett, Steven Price, Scott Schatz and Stuart B. Rosenstein in 1994 and is headquartered in Purchase, NY.

Townsquare Media Inc - Ordinary Shares - Class A

TSQ is trending due to mixed sentiment regarding its digital transformation and upcoming earnings, with some investors concerned about government advertising declines and potential disappointing forecasts. The community is debating whether it's worth holding through the Fed Meeting and earnings report, while others point to the company's AI strategy and analyst reports with a longer-term positive outlook. Broader discussions involve the impact of weakening macroeconomic conditions and potential risks to the dividend yield.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around this OG meme coin. Advocates emphasize its strong community, cultural significance, and potential within the meme coin sector. Social media mentions are focused on community building and aiming for the moon.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

$CAW is trending as community members rally around the meme coin, emphasizing its strong community and unique deflationary tokenomics. The multichain functionality across $SOL, $ETH, and $CRO using LayerZero is a key talking point, with many expressing bullish sentiment and encouraging others to join the 'crow with knife' movement.

ArcelorMittal SA is a holding company, which engages in steelmaking and mining activities. It operates through the following business segments: NAFTA; Brazil; Europe; Africa and Commonwealth of Independent States (ACIS), and Mining. The NAFTA segment consists of flat products such as slabs, hot-rolled coil, cold-rolled coil, coated steel, and plate. The Brazil segment covers wire rod, bar and rebars, billets, blooms, and wire drawing. The Europe segment offers hot-rolled coil, cold-rolled coil, coated products, tinplate, plate, and slab. The ACIS segment produces a combination of flat, long, and tubular products. The Mining segment focuses on steel operations. The company was founded by Lakshmi Niwas Mittal in 1976 and is headquartered in Luxembourg.

ArcelorMittal - New York Shares - Level III

Arcelor Mittal

ArcelorMittal ($MT) is trending due to JPMorgan's recent upgrade to Overweight following reassuring Q3 results and a strong Q4 free cash flow outlook, sparking bullish sentiment. The community is discussing the potential for the stock to reach $50 and unusual options activity with call flow, while some remain skeptical due to the company's ownership structure and historical performance. Broader context includes discussions around materials sector corrections and potential new advancements in steelmaking with electric heating tech.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as the community discusses its potential within the AI sector and recent price volatility. Some speculate on a bullish reversal and are loading up, while others point to Zcash potentially driving interest in NEAR. Discussions also mention staking options and cross-chain capabilities as potential catalysts.

LyondellBasell Industries NV engages in the refinery and production of plastic resins and other chemicals. It operates through the following segments: Olefins and Polyolefins-Americas; Olefins and Polyolefins-Europe, Asia, International; Intermediates and Derivatives; Advanced Polymer Solutions; Refining; and Technology. The Olefins and Polyolefins-Americas segment produces and markets olefins and co-products, polyethylene and polypropylene. The Olefins and Polyolefins-Europe, Asia, International segment also offers olefins and polyolefins. The Intermediates and Derivatives segment includes propylene oxide and its derivatives; oxyfuels and related products; and intermediate chemicals. The Advanced Polymer Solutions segment produces and markets compounding and solutions, such as polypropylene compounds, engineered plastics, masterbatches, colors and powders, engineered composites, and advanced polymers. The Refining segment refines heavy, high-sulfur crude oil and other crude oils of varied types and sources. The Technology segment develops chemical and polyolefin process technologies and manufactures and sells polyolefin catalysts. The company was founded in December 2007 and is headquartered in London, the United Kingdom.

LyondellBasell Industries NV - Ordinary Shares - Class A

LYB is trending due to recent price declines and upcoming earnings, with investors closely watching whether the company will maintain its dividend. The community is debating the stock's valuation, potential for a turnaround, and whether current prices present a buying opportunity or signal further downside. Discussions also include the broader impact of economic conditions and sector-specific challenges on LYB's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Eli Lilly CEO Dave Ricks' comments come after the company reported third-quarter earnings results that topped estimates and hiked its full-year guidance.</li><li>Ricks stated “triple-acting” Retatrutide promises to have an even bigger impact on weight loss than Zepbound and Mounjaro.</li><li>In addition to its injectable therapies, the launch of Orforglipron, a daily oral pill for weight loss, is also in the pipeline.</li></ul>Eli Lilly (LLY) is reportedly looking to expand into pain relief by leveraging the momentum of its weight loss treatments, Mounjaro and Zepbound, which have captured significant share in the fast-growing obesity market.CEO Dave Ricks&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/10/30/watch-cnbcs-full-interview-with-eli-lilly-ceo-dave-ricks.html">told</a> CNBC on Thursday that the company sees potential to move beyond traditional weight management into therapies that address pain associated with obesity. According to the company’s third-quarter earnings report, trials are underway targeting knee and back pain, with a focus on patients who are overweight or have obesity.<blockquote>“We hope to prove that patients who are overweight or have obesity with chronic knee pain find relief with Retatrutide in addition to losing weight.”&nbsp;– Dave Ricks, CEO, Eli Lilly</blockquote>Ricks stated “triple acting” Retatrutide promises to have an even bigger impact on weight loss than Zepbound and Mounjaro.&nbsp; “The first study that we’ll read out for that triple-acting agent will actually be in knee pain,” he said, adding that weight loss drugs have both direct and indirect anti-inflammatory effects.<h2 class="st-heading-2">Eli Lilly Hikes Full-Year Guidance</h2>Ricks’ comments follow the company's upbeat third-quarter (Q3) results and increased full-year guidance, issued earlier on Thursday. The pharmaceutical giant now expects its fiscal 2025 revenue to be between $63 billion and $63.5 billion, up from its previous guidance of $60 billion to $62 billion.<a href="http://stocktwits.com/symbol/LLY">LLY’s stock</a> gained 3.7% in morning trade, with retail sentiment around the pharma giant on Stocktwits improving to ‘bullish’ from ‘bearish’ territory over the past day. Retail chatter increased to ‘high’ from ‘low’ levels.Lilly reported a strong international uptake for its products, rolling out Mounjaro earlier this year in markets including India, China, and Brazil. “We’re seeing global demand for this product,” the CEO said, adding that both Mounjaro and Zepbound have performed well in their early years, signaling the potential for sustained growth in the future.<h2 class="st-heading-2">Oral Pill Expansion</h2>In addition to its injectable therapies, Lilly is preparing to launch Orforglipron, a daily oral pill, which Ricks said has completed Phase 3 trials, with submission expected in Q4. The CEO highlighted that oral therapy meets patient demand for a less intrusive option than weekly injections.&nbsp;He said it also addresses practical barriers in middle-income countries where refrigeration and cold-chain requirements limit access to injectable products. “We think that’s a great spot for Orforglipron,” the CEO noted, adding that the company expects strong global performance for Orforglipron.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-dips-triggers-800-million-in-crypto-liquidations-after-powells-warning/cLGFrJnR3Dy">Bitcoin Dips, Triggers $800 Million In Crypto Liquidations After Powell’s December Warning</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CEO of Eli Lilly and Company David Ricks speaks at the Economic Club of New York on March 12, 2024 in New York City. (Photo by Spencer Platt/Getty Images)

Eli Lilly CEO Dave Ricks Reportedly Says Company Eyeing Pain Relief Market With Weight Loss Drug Retatrutide 

CEO Dave Ricks told CNBC that the first study the company plans to read out for Retatrutide will be on knee pain.

Eli Lilly CEO Dave Ricks Reportedly Says Company Eyeing Pain Relief Market With Weight Loss Drug Retatrutide

Equity

UnitedHealth Lifts EPS Outlook Despite Mixed Q3 Results: ETFs in Focus

UNH posts mixed Q3 results with a revenue miss but lifts its 2025 EPS outlook, boosting interest in healthcare ETFs like IHF and XLV. 

<ul class="summary-bullets"><li>Short seller Hunterbrook flagged three new deaths linked to the Dexcom G7 reported in&nbsp;the FDA MAUDE database.</li><li>It stated that at least 13 G7 users have died since the device launched in 2023.&nbsp;</li><li>This is&nbsp;the second time the firm has published data around Dexcom, after first disclosing its short position in September.</li></ul>Dexcom (DXCM) shares slipped in midday trade on Tuesday after short seller Hunterbrook reported three additional deaths linked to the company’s G7 continuous glucose monitor.<a href="http://stocktwits.com/symbol/DXCM">DXCM’s stock</a> fell nearly 2%, with retail sentiment on Stocktwits around the company trending in ‘bearish’ territory over the past day.&nbsp; Hunterbrook first&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dexcom-stock-slumps-after-hunterbrook-media-investigation-raises-concerns-about-its-g7-device/chD3f5NR3Tm">disclosed</a> its short position in September, citing inaccurate G7 readings that allegedly sent patients to ICUs or&nbsp;led to worse outcomes.&nbsp;<h2 class="st-heading-2">FDA Data Shows Device Risks</h2>The short seller&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/dexcom2/">said</a> the new deaths were documented in the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, which tracks adverse events involving medical devices. It noted that while the reports do not necessarily prove the device caused the deaths, they help regulators and manufacturers flag potential risks.Hunterbook highlighted that one report described a 69-year-old man whose G7 sensor failed to provide readings, and a second involved a patient using the G7 with an automated insulin pump, whose inaccurate reading may have contributed to fatal ketoacidosis. The third report cited a woman who relied on the G7’s receiver alarms, which had been recalled days earlier for failing to sound properly.<h2 class="st-heading-2">Ongoing Scrutiny And Product Concerns</h2>The short seller stated that at least 13 G7 users have died since the device launched in 2023.&nbsp;It said that even the FDA issued a warning letter to Dexcom in March 2025 following a surprise inspection that revealed unauthorized design changes to a key component, which internal testing found inferior.&nbsp;Dexcom reportedly continued selling the device despite these findings. The short seller stated that the resulting controversy has triggered executive departures, insider selling, and patients returning to older G6 devices or switching to competitors, while ongoing lawsuits and regulatory scrutiny weigh on the company.DXCM’s stock has declined 11% this year and more than 8% since Hunterbrook first disclosed its short position.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-holds-near-114-k-ahead-of-fed-rate-decision-sol-xrp-edge-higher/cLGjgObR3H9">Bitcoin Holds Near $114K Ahead of Fed Rate Decision — SOL, XRP Edge Higher</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Dexcom Shares Slide After Short Seller Flags 3 Additional Deaths From G7 Devices

Short seller Hunterbrook stated that at least 13 G7 users have died since the device launched in 2023. 

<ul class="summary-bullets"><li>While the consensus EPS estimate suggests a decline from a year ago, revenue is expected to rise by more than 12% year over year.</li><li>A retail user expected a “well-thought-out earnings call with a road to a bright future, no matter what the numbers say.”</li><li>Stung by the headwinds, UnitedHealth stock is down more than 23% this year.</li></ul>Healthcare services giant UnitedHealth, Inc. (UNH), which has been facing company-specific, macro, and geopolitical challenges, is scheduled to announce its quarterly results before the market opens on Tuesday.Stung by the headwinds,&nbsp;<a href="https://stocktwits.com/symbol/UNH">UnitedHealth stock</a> is down more than 23% this year.<h2 class="st-heading-2">What Street Expects For UNH’s Q3</h2>According to the Fiscal.ai-compiled consensus estimates, UnitedHealth is expected to report adjusted earnings per share (EPS) of $2.81 and revenue of $113.06 billion. While the consensus EPS estimate suggests a decline from the year-ago’s $3.57, revenue is expected to rise over 12% year-over-year (YoY).In a mid-September note, Morgan Stanley analyst Erin Wright said he came away from an investor dinner with the UNH management team incrementally positive. He noted that the management team, led by CEO Stephen Hemsley, oozed conviction in a turnaround, driven by Medicare Advantage (MA) and Optum Health improvement.Among the headwinds the company faces are higher medical loss ratios that have pressured margins, pricing,&nbsp;as well as operational mistakes in its MA and Affordable Care Act (ACA) businesses.&nbsp;It also faces criminal investigations into the MA billing practices, and the business practices of its&nbsp;Optimum unit, as well as other lawsuits for allegedly improperly denying claims.The company withdrew its full-year 2025 guidance in mid-May, replaced Andrew Witty as CEO with former CEO Hemsley, citing unexpected medical costs and challenges with its Medicare strategy. It, however, reinstated the annual guidance when it released its second-quarter results in late July. The current outlook calls for revenue of $445.5 billion to $448 billion and adjusted EPS of at least $16.<h2 class="st-heading-2">How Retail Is Positioned For Q3 Results</h2>Retail sentiment toward UnitedHealth stock flipped to ‘bullish’ by early Tuesday from ‘bearish’ a day ago. The message volume on the stream has picked up pace to ‘high’ levels.<figure class="image"><img style="aspect-ratio:623/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_28_at_1_35_06_AM_png_d1fda1994a.webp" alt="Screenshot 2025-10-28 at 1.35.06 AM.png" width="623" height="53"><figcaption>UNH sentiment and message volume as of 1:30 a.m ET, Oct. 28 | source: Stocktwits</figcaption></figure>A bullish user looked ahead to better performance after a “kitchen-sink” second quarter.<stembedurl>https://stocktwits.com/newtwo99/message/633929931</stembedurl>Another user expected a “well-thought-out earnings call with a road to a bright future no matter what the numbers say.” If the numbers come in better than expected, they see it as an added advantage.<stembedurl>https://stocktwits.com/PhoenixRisingMD/message/633928829</stembedurl><h2 class="st-heading-2">Wall Street Lift Price Targets Ahead Of Q3 Print</h2>Since the start of October, UnitedHealth’s stock has received a string of price target hikes, with the updated price targets ranging from $335 to $433, according to the Fly. While lifting its price target to $409 from $317 earlier this month, Jefferies analyst David Windley said he sees upside for MA margins in 2026, thanks to assertive group repricing efforts. The analyst has a ‘Buy’ rating on the stock.Goldman Sachs initiated coverage of the UnitedHealth stock with a ‘Buy rating’ and $406 price target. While the firm believes that the managed care industry faces its most significant underwriting downturn in over 15 years, it recommended increased exposure to MA, factoring in a margin recovery phase beginning in 2026.&nbsp;After bumping up the price target to $430 from $300, Mizuho, which has an ‘Overweight’ rating, noted increased earnings visibility on key issues and rotation into the healthcare sector.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-nxp-semiconductor-stock-rose-in-today-s-after-hours/cLGjTBXR3ur">Why NXP Semiconductor Stock Rose In Today’s After-hours</a>

In this photo illustration, a smartphone displays the logo of UnitedHealth Group Incorporated. (Photo illustration by Cheng Xin/Getty Images)

UnitedHealth Stock In Spotlight Ahead Of Earnings: Retail Traders Bet On Recovery After ‘Kitchen-Sink’ Q2

While the consensus EPS estimate suggests a decline from a year ago, revenue is expected to rise by more than 12% year over year.

UnitedHealth (UNH) Stock In Spotlight Ahead Of Earnings: Retail Traders Bet On Recovery After ‘Kitchen-Sink’ Q2

4 Sector ETFs & Stocks to Gain Despite Lower-Than -Expected Inflation

September records lower-than-expected inflation! Energy (OIH), Restaurants (EATZ), Healthcare (XLV) and Transportation (XTN) ETFs may still shine in the near term.

Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs

Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs. 

<ul class="summary-bullets"><li>The Trump administration is preparing a Section 301 investigation to assess whether U.S. trading partners underpay for prescription drugs, a move that could pave the way for new tariffs.</li><li>Earlier this month, the White House confirmed generic drugs would be excluded from potential duties, reversing earlier discussions under the Section 232 national security review.</li><li>The probe expands Trump’s broader effort to pressure pharmaceutical companies and foreign governments to “equalize” drug prices globally.</li></ul>President Donald Trump’s administration reportedly is stepping up pressure on U.S. trading partners over drug costs, preparing a Section 301 investigation under the Trade Act of 1974 to determine whether countries are underpaying for prescription medicines.The move could pave the way for new tariffs and marks a renewed escalation in Trump’s campaign to “equalize” drug prices globally, according to a Financial Times&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/bce66d6e-57f7-40a2-8225-06a8f50ff657">report</a>, citing three people familiar with the matter.Trump has long argued Americans pay disproportionately high prices for the same drugs sold abroad, citing last week that “in London, you’d buy a certain drug for $130 … and in New York, you pay $1,300 for the same thing.”&nbsp;U.S. drug prices average nearly three times higher than in other developed economies, according to the Rand Corporation. Novo Nordisk’s Ozempic, for instance, costs about $936 per month in the U.S., versus $147 in Canada and $83 in France, KFF data show.<h2 class="st-heading-2">Generic Drugs Excluded From Tariff Plans</h2>Earlier this month, the White House<a href="https://stocktwits.com/news-articles/markets/equity/trump-walks-back-generic-drug-tariffs-after-white-house-clash-over-prices-supply-risks/ch67JdhR30E"> said it isn’t planning tariffs on generic drugs</a>, narrowing the scope of its trade actions. Officials had been weighing such duties under Section 232 of the Trade Expansion Act, which permits tariffs on national security grounds.White House spokesman Kush Desai said the administration “is not actively discussing imposing Section 232 tariffs against generic pharmaceuticals.” The Commerce Department also said such tariffs were unlikely, marking a reversal from Trump’s 2023 campaign pledge to restore domestic production of all essential medicines.Advisers, including members of the Domestic Policy Council and health aide Theo Merkel, warned tariffs on generics could raise prices and cause shortages, given that India supplies nearly half of U.S. generic drugs. Commerce officials, however, continue to explore quotas or incentives to rebuild U.S. drug manufacturing capacity.<h2 class="st-heading-2">Broader Pharma Trade Push&nbsp;</h2>The Section 301 move expands Trump’s broader effort to tie drug pricing policy to trade leverage. Earlier this year, he demanded that pharmaceutical companies offer the U.S. their best global price or face penalties.Major firms, including Pfizer, AstraZeneca, Novo Nordisk, and Eli Lilly, have all held pricing talks with the White House. Trump previously reached a deal with the EU to cap drug import tariffs at 15% and is negotiating with the U.K. for lower duties in exchange for higher payments to drugmakers.While Trump last month threatened 100% tariffs on branded drugs to force companies to expand U.S. manufacturing, those measures have yet to materialize. Officials said firms will be given time to invest domestically and demonstrate pricing reforms.Desai said the White House is pursuing a “multi-faceted approach” that could include federal grants or loans, potentially with funding from foreign partners like Japan, to strengthen U.S. drug supply chains and reduce dependence on imports.<h2 class="st-heading-2">Stocktwits Traders See Muted Interest For Healthcare ETFs</h2>On Stocktwits, retail sentiment toward the Health Care Select Sector SPDR Fund (XLV) was ‘bearish’ and toward the iShares Global Healthcare ETF (IXJ) was ‘neutral,’ both amid ‘low’ message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> is up 7%, while&nbsp;<a href="https://stocktwits.com/symbol/IXJ">IXJ</a> has gained 9%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

Trump Steps Up Pressure On Trading Partners Over Drug Costs, Plans Section 301 Review: Report

The probe expands Trump’s broader effort to pressure pharmaceutical companies and foreign governments to “equalize” drug prices globally.

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

Zacks Investment Ideas feature highlights: XLP, KXI, XLU, VPU, VHT and XLV

As AI-fueled markets show bubble risks, defensive ETFs like XLP, XLU, and XLV offer investors stability and downside protection.

SSgA Active Trust - Health Care Select Sector SPDR

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

XLV
Health Care Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XLV News

XLVHealth Care Select Sector SPDR Fund